Richard Clark, DO
Family Medicine · Evansville, INNPI 1437387040
Payments from drug & device makers
Across 117 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$308
- Pfizer$228
- Lilly USA, LLC$216
- AstraZeneca$140
- Novo Nordisk$134
- Axsome Therapeutics, Inc.$113
- plus $571 from 19 others
What the payments were for
- Food & beverage$1,66597%
- Education$453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $308 |
| Pfizer | 15 | $228 |
| Lilly USA, LLC | 13 | $216 |
| AstraZeneca | 9 | $140 |
| Novo Nordisk | 9 | $134 |
| Axsome Therapeutics, Inc. | 8 | $113 |
| Novartis | 5 | $74 |
| Amgen | 5 | $71 |
| Corium, LLC | 5 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Abbott | 3 | $51 |
| Merck | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Shield Therapeutics Inc | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Sonex Health, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$1,710 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 138 | $147,524 |
| MysolinePrimidone | 13 | $74,158 |
| EliquisApixaban | 33 | $42,593 |
| MounjaroTirzepatide | 44 | $42,001 |
| TrulicityDulaglutide | 27 | $35,108 |
| JanuviaSitagliptin Phosphate | 31 | $27,263 |
| MyrbetriqMirabegron | 35 | $19,888 |
| XareltoRivaroxaban | 22 | $11,657 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,111 |
| TradjentaLinagliptin | 13 | $10,964 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $9,716 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,047 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $8,341 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,979 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $7,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $134 | $147,524138 claims |
| Lilly USA, LLCMounjaro, Trulicity | $216 | $77,10971 claims |
| PfizerEliquis | $228 | $42,59333 claims |
| MerckJanuvia | $29 | $27,26331 claims |
| Boehringer IngelheimTradjenta, Spiriva Respimat | $15 | $18,94328 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $140 | $16,24431 claims |
| GSKBreo Ellipta | $20 | $9,04714 claims |
| AbbVieSynthroid | $308 | $1,84717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Alexander Dela LlanaEvansville$1.6M
- David BrougherEvansville$556K
- Anthony InzerelloEvansville$338K
- James GutmannEvansville$311K
- Randall StoltzEvansville$248K
- William SmithEvansville$150K
- Carol GoodmanEvansville$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.